A Higher Rate of Pulmonary Fungal Infection in Chronic Obstructive Pulmonary Disease Patients with Influenza in a Large Tertiary Hospital

Background: Influenza is considered a self-limiting disease. However, in patients with chronic obstructive pulmonary disease (COPD), it may result in serious outcomes during the flu season. Objectives: The aims of this retrospective study were to explore the characteristics of hospitalized patients with COPD complicated by influenza and determine the factors affecting the prognosis of these patients. Method: Demographic and clinical data were collected for 278 patients totally from the West China Hospital between January 1, 2016 and February 28, 2018. Results: Among the patients with influenza, the positive fungal culture rate, and the rates of antifungal drug and systemic corticosteroids use were higher for those with COPD than for those without COPD. Respiratory failure was more common in patients with influenza and COPD than in patients with influenza only, while the proportion of severe cases was higher among the former than among the latter. Among the patients with COPD, the positive fungal culture rate, particularly for Aspergillus, and the rate of systemic corticosteroids use were higher for those with influenza than for those without influenza. Multivariate analysis revealed that a COPD history of >20 years and smoking for >20 pack-years were independent factors for susceptibility of COPD patients to influenza. Conclusions: Aspergillus infection seems to be more common in patients with influenza and COPD. In addition, COPD complicated by influenza during the seasonal outbreak can easily progress to a severe disease state. Heavy smokers and patients with a prolonged COPD history are more likely to be infected by influenza.

[1]  Meilan K. Han,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 , 2019, European Respiratory Journal.

[2]  Yongjian Xu,et al.  Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study , 2018, The Lancet.

[3]  C. Vogelmeier,et al.  Exacerbations of COPD , 2018, European Respiratory Review.

[4]  T. Sorrell,et al.  Influenza A Virus as a Predisposing Factor for Cryptococcosis , 2017, Front. Cell. Infect. Microbiol..

[5]  G. Huffnagle,et al.  The significance of Candida in the human respiratory tract: our evolving understanding , 2017, Pathogens and disease.

[6]  P. Thomas,et al.  Viruses are frequently present as the infecting agent in acute exacerbations of chronic obstructive pulmonary disease in patients presenting to hospital , 2016, Internal medicine journal.

[7]  C. Roberts,et al.  Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit , 2015, European Respiratory Journal.

[8]  H. Badali,et al.  Aspergillus colonization in patients with chronic obstructive pulmonary disease , 2015, Current medical mycology.

[9]  Te-Wei Ho,et al.  In-Hospital and One-Year Mortality and Their Predictors in Patients Hospitalized for First-Ever Chronic Obstructive Pulmonary Disease Exacerbations: A Nationwide Population-Based Study , 2014, PloS one.

[10]  D. Mannino,et al.  Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013 , 2014, International journal of chronic obstructive pulmonary disease.

[11]  A. Torres,et al.  Importance of Aspergillus spp. isolation in Acute exacerbations of severe COPD: prevalence, factors and follow-up: the FUNGI-COPD study , 2014, Respiratory Research.

[12]  K. Kwon-Chung,et al.  Aspergillus fumigatus—What Makes the Species a Ubiquitous Human Fungal Pathogen? , 2013, PLoS pathogens.

[13]  Zijian Feng,et al.  Seasonal Influenza Vaccination Coverage Rate of Target Groups in Selected Cities and Provinces in China by Season (2009/10 to 2011/12) , 2013, PloS one.

[14]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[15]  O. Rutschmann,et al.  Upper-Respiratory Viral Infection, Biomarkers, and COPD Exacerbations , 2010, Chest.

[16]  D. Kontoyiannis,et al.  Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection , 2010, British journal of haematology.

[17]  T. Peláez,et al.  Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[18]  A. Anzueto,et al.  Impact of exacerbations on COPD , 2010, European Respiratory Review.

[19]  B. Chuaychoo,et al.  The immunogenicity of intradermal influenza vaccination in COPD patients. , 2010, Vaccine.

[20]  R. Medzhitov,et al.  Influenza virus-induced glucocorticoids compromise innate host defense against a secondary bacterial infection. , 2010, Cell host & microbe.

[21]  M. Meade,et al.  Critically ill patients with 2009 influenza A(H1N1) infection in Canada. , 2009, JAMA.

[22]  Dongxu Xie,et al.  Apoptosis of lymphocytes and monocytes infected with influenza virus might be the mechanism of combating virus and causing secondary infection by influenza. , 2009, International immunology.

[23]  M. Boeckh,et al.  Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[24]  W. Peetermans,et al.  Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study , 2009, Intensive Care Medicine.

[25]  T. MacDonald,et al.  Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD , 2009, Thorax.

[26]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  D. Weiskopf,et al.  Biology of immune responses to vaccines in elderly persons. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  S. Johnston,et al.  Influenza infection and COPD , 2007, International journal of chronic obstructive pulmonary disease.

[29]  G. Wesseling.  Occasional review: Influenza in COPD: pathogenesis, prevention, and treatment , 2007, International journal of chronic obstructive pulmonary disease.

[30]  L. Fabbri,et al.  Pathophysiology of exacerbations of chronic obstructive pulmonary disease. , 2006, Proceedings of the American Thoracic Society.

[31]  R. Stockley,et al.  COPD exacerbations · 2: Aetiology , 2006, Thorax.

[32]  F. Colardyn,et al.  Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients , 2006, Critical care.

[33]  J. Treanor,et al.  Fever and progressive respiratory failure in three elderly family members. , 2005, Chest.

[34]  W. Dejsomritrutai,et al.  Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. , 2004, Chest.

[35]  J. Cadranel,et al.  Significance of Aspergillus fumigatus Isolation from Respiratory Specimens of Nongranulocytopenic Patients , 2003, European Journal of Clinical Microbiology and Infectious Diseases.

[36]  A. Gillissen,et al.  Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study , 2003, Thorax.

[37]  C. Clancy,et al.  Acute community-acquired pneumonia due to Aspergillus in presumably immunocompetent hosts: clues for recognition of a rare but fatal disease. , 1998, Chest.

[38]  G. Baum.  The significance of Candida albicans in human sputum. , 1960, The New England journal of medicine.

[39]  A. Buist,et al.  Gaps in using bronchodilators, inhaled corticosteroids and influenza vaccine among 23 high- and low-income sites. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[40]  S. Zanotti-Cavazzoni.  Critically Ill Patients With 2009 Influenza A(H1N1) Infection in Canada , 2011 .

[41]  V. Preedy,et al.  European Organization for Research and Treatment of Cancer , 2010 .

[42]  A. Wilmer,et al.  Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. , 2008, American journal of respiratory and critical care medicine.

[43]  A. Malik,et al.  Mycological and serological study of pulmonary Aspergillosis in central India. , 2003, Indian journal of medical microbiology.